Gilead Sciences, Inc. company logo

# 1st Gen Model Gilead Sciences, Inc. Biological products, except diagnostic

Subscribe >> Deal exit on
Dec. 15, 2017
Deal entry on
Dec. 15, 2017
0.47%Expected margin
59.78% successful of 92 deals
$74.34 Last close price
at 14-dec-2017

GILD

Model's trade recommendations 3.51% Return for period

-3.24% Annual return

$100.03B Market Cap

β 1.13  

GILD

Model (following trade recommendations)

GILD

Underlying stock

S&P 500

Index
Return for period 3.51%
2.67%
1.78%
52wk return -1.32%
-1.60%
16.82%
52wk Range
64.12—85.47
2000.54—2399.63
Sortino ratio -0.27
Sharpe ratio -0.22
Norm. RMSE 0.30%
Downside risk 10.50%
Volatility 12.78%
  • 2.08 (2.72%) Div (Yield)
  • BUY Analysts consensus recommendation

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. They strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead Sciences portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 23, 2015.

Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1289M
P/E 7.99
Shares Outstanding 1306M
% Held by Insiders 1.30%
% Held by Institutions 76.23%
EPS (last reported FY) $11.37
EPS (last reported Q) $2.23
EPS, estimated (last reported Q) $2.03
Total revenues $30 B
Net income $14 B